Indications
Therapeutic Asset Ratings
6,305 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tinengotinib
Prostate Cancer
Memorial Sloan Kettering Cancer Center
P1/2
CC
(46)
Tislelizumab
Endometrial Carcinoma
Hutchmed
P1/2
CC
(46)
tj-68
Amyotrophic Lateral Sclerosis
Hiroshi Mitsumoto
P1/2
CC
(46)
Tolinapant
Fallopian Tube Carcinosarcoma
National Cancer Institute (NCI)
P1/2
CC
(46)
Tolinapant
Ovarian Carcinosarcoma
National Cancer Institute (NCI)
P1/2
CC
(46)
Tumor-Draining Lymph Node-Derived Lymphocyte
Breast Neoplasm
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
P1/2
CC
(46)
Utomilumab
Metastatic Prostate Carcinoma
M.D. Anderson Cancer Center
P1/2
CC
(46)
Utomilumab
Prostate Cancer
M.D. Anderson Cancer Center
P1/2
CC
(46)
Vorinostat
Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
P1/2
CC
(46)
Wrair-Pam-Cf1
Cystic Fibrosis
National Institute of Allergy and Infectious Diseases (NIAID)
P1/2
CC
(46)
Zanidatamab
Gastroesophageal Junction Adenocarcinoma
Boehringer Ingelheim
P1/2
CC
(46)
Zanzalintinib
Non-Small Cell Lung Carcinoma
Exelixis
P1/2
CC
(46)
zx-101a
Non-Hodgkin Lymphoma
Nanjing Zenshine Pharmaceuticals
P1/2
CC
(46)
zx-101a
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Nanjing Zenshine Pharmaceuticals
P1/2
CC
(46)
1.0% ip-001 for
Soft Tissue Sarcoma
Immunophotonics, Inc.
P1/2
CC
(45)
161tb rad402
Castration-Resistant Prostate Carcinoma
Radiopharm Theranostics, Ltd
P1/2
CC
(45)
177lu-betabart
Non-Small Cell Lung Carcinoma
Radiopharm Theranostics, Ltd
P1/2
CC
(45)
[177lu]lu-dpi-4452
Urothelial Carcinoma
ITM Oncologics GmbH
P1/2
CC
(45)
18f-op-801
Amyotrophic Lateral Sclerosis
Ashvattha Therapeutics, Inc.
P1/2
CC
(45)
18f-op-801
Parkinson Disease
Ashvattha Therapeutics, Inc.
P1/2
CC
(45)
[203Pb]Pb-MP0712
Small Cell Lung Carcinoma
Molecular Partners AG
P1/2
CC
(45)
[203pb]pb-psv359
Mesothelioma
Perspective Therapeutics
P1/2
CC
(45)
[212pb]pb-mp0712
Small Cell Lung Carcinoma
Molecular Partners AG
P1/2
CC
(45)
[212pb]pb-psv359
Mesothelioma
Perspective Therapeutics
P1/2
CC
(45)
225ac-sso110
Cutaneous Neuroendocrine Carcinoma
Ariceum Therapeutics GmbH
P1/2
CC
(45)
Showing 2851 to 2875 of 6,305 assets
Previous
Page 115 of 253
Next